| 12486277 |
CDK inhibitors and their use as pharmaceuticals |
Lijin Lu, Rupa Shetty, Chaofeng Dai, Raul Andrew Leal, Klare Lazor Bersch |
2025-12-02 |
|
| 12448389 |
BRM targeting compounds and associated methods of use |
Lijin Lu, Corey Howard Basch, Rupa Shetty, Chaofeng Dai, Klare Lazor Bersch +3 more |
2025-10-21 |
|
| 12421197 |
Aminopyrazine derivatives as PI3K-γ inhibitors |
Brent Douty, Yanran Ai, David M. Burns, Nikoo Falahatpisheh, Daniel Levy +6 more |
2025-09-23 |
|
| 12365668 |
Aminopyrazine diol compounds as PI3K-y inhibitors |
Stacey Shepard, Nikoo Falahatpisheh, Lixin Shao |
2025-07-22 |
|
| 12227502 |
1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c] pyridin-7(6H)-ones as inhibitors of BET proteins |
Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh |
2025-02-18 |
|
| 12201636 |
Heterocyclylamines as PI3K inhibitors |
Yun-Long Li, Wenqing Yao, Eddy W. Yue, Song Mei, Joseph Glenn +2 more |
2025-01-21 |
|
| 12173006 |
Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor |
Brent Douty, David M. Burns, Zhongjiang Jia, Daniel Levy, Eddy W. Yue |
2024-12-24 |
$95,588,000 |
| 12152033 |
Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders |
Yun-Long Li, Eddy W. Yue, Song Mei, Brent Douty |
2024-11-26 |
$37,065,000 |
| 12129262 |
CDK inhibitors and their use as pharmaceuticals |
Xiaowei Wu, Andrew W. Buesking, Ryan Holmes, Sarah Pawley, Katarina Rohlfing |
2024-10-29 |
$1,622,000 |
| 12030885 |
Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors |
Andrew W. Buesking, Richard B. Sparks, Brent Douty, Nikoo Falahatpisheh, Lixin Shao +5 more |
2024-07-09 |
$15,981,000 |
| 12006320 |
Heterocyclic derivatives as PI3K inhibitors |
Stacey Shepard, Yanran Ai, Nikoo Falahatpisheh, Lixin Shao, Artem Shvartsbart |
2024-06-11 |
$44,848,000 |
| 11999751 |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
Yun-Long Li |
2024-06-04 |
$26,035,000 |
| 11952367 |
Pyridine and pyridimine compounds as PI3K-gamma inhibitors |
Richard B. Sparks, Stacey Shepard, Andrew W. Buesking, Lixin Shao, Haisheng Wang +1 more |
2024-04-09 |
$75,635,000 |
| 11939340 |
CDK inhibitors and their use as pharmaceuticals |
Jincong Zhuo, Xiaowei Wu, Katarina Rohlfing |
2024-03-26 |
$4,239,000 |
| 11926630 |
Tertiary alcohols as PI3K-γ inhibitors |
Brent Douty, Andrew W. Buesking, David M. Burns, Nikoo Falahatpisheh, Ravi Kumar Jalluri +7 more |
2024-03-12 |
$38,520,000 |
| 11926616 |
Aminopyrazine diol compounds as PI3K-γ inhibitors |
Stacey Shepard, Nikoo Falahatpisheh, Lixin Shao |
2024-03-12 |
$38,520,000 |
| 11819505 |
Heterocyclylamines as PI3K inhibitors |
Yun-Long Li, Eddy W. Yue, Brent Douty, Song Mei |
2023-11-21 |
$64,645,000 |
| 11773102 |
Heterocyclic compounds as PI3K-γ inhibitors |
Artem Shvartsbart, Stacey Shepard, Lixin Shao, Nikoo Falahatpisheh, Ge Zou +4 more |
2023-10-03 |
$78,215,000 |
| 11702423 |
BRM targeting compounds and associated methods of use |
Hong-Nien Lin, Philip Pitis, Liang Lu |
2023-07-18 |
$3,762,000 |
| 11702416 |
1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins |
Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh |
2023-07-18 |
$87,872,000 |
| 11685744 |
CDK inhibitors and their use as pharmaceuticals |
Andrew W. Buesking, Jincong Zhuo, Ryan Holmes, Sarah Pawley, Xiaowei Wu |
2023-06-27 |
$4,573,000 |
| 11673893 |
CDK inhibitors and their use as pharmaceuticals |
Liang Lu, Rupa Shetty, Chaofeng Dai, Raul Andrew Leal, Klare Lazor Bersch |
2023-06-13 |
$5,428,000 |
| 11622970 |
BCL-2 inhibitors and their use as pharmaceuticals |
Jincong Zhuo, Peng Wei, Jialiang Wang |
2023-04-11 |
|
| 11498926 |
Tricyclic heterocycles as BET protein inhibitors |
Richard B. Sparks, Thomas P. Maduskuie, Jr., James D. Rodgers |
2022-11-15 |
$55,741,000 |
| 11433071 |
Heterocyclylamines as PI3K inhibitors |
Yun-Long Li, Wenqing Yao, Eddy W. Yue, Song Mei, Joseph Glenn +4 more |
2022-09-06 |
$107,454,000 |
